Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

omalizumab

omalizumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Omlyclo INJECTION, SUBCUTANEOUS 75 mg/0.5 mL, 150 mg/mL    
Xolair INJECTION, SUBCUTANEOUS 75 mg/0.5 mL, 150 mg/mL    
Xolair POWDER FOR INJECTION, SUBCUTANEOUS 150 mg    
VIEW MORE Respiratory Tract Agents, Miscellaneous
CLASS
489200
Comments:

Xolair medication guide

Xolair and all biosimilars reviewed by the Committee are classified as therapeutically equivalent and interchangeable and formulary, restricted to the hospital outpatient setting. The most cost-effective product will be used for a specific patient, setting, or time period.

 

Inpatients should use home supply.

 

For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents 

 

 

Reviewed: August 2025

Omalizumab-igec (OMLYCLO) Spotlight.pdf

 

Last updated: Sep. 10, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved